Candel Therapeutics Analyst Ratings
Candel Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 1096.17% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 05/22/2023 | 1096.17% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 05/15/2023 | 226.23% | BMO Capital | $9 → $3 | Maintains | Outperform |
| 03/31/2023 | 661.2% | Credit Suisse | $8 → $7 | Maintains | Outperform |
| 12/07/2022 | 769.94% | Credit Suisse | $10 → $8 | Maintains | Outperform |
| 12/02/2022 | 1096.17% | HC Wainwright & Co. | → $11 | Initiates Coverage On | → Buy |
| 03/31/2022 | 1204.92% | BMO Capital | $18 → $12 | Maintains | Outperform |
| 11/19/2021 | 1857.37% | BMO Capital | → $18 | Initiates Coverage On | → Outperform |
| 08/23/2021 | 878.69% | UBS | → $9 | Initiates Coverage On | → Buy |
| 08/23/2021 | 2292.34% | Jefferies | → $22 | Initiates Coverage On | → Buy |
| 08/23/2021 | 1531.14% | Credit Suisse | → $15 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/13/2023 | 1096.17% | HC Wainwright & Co. | → 11 美元 | 重申 | 购买 → 购买 |
| 05/22/2023 | 1096.17% | HC Wainwright & Co. | → 11 美元 | 重申 | 购买 → 购买 |
| 05/15/2023 | 226.23% | BMO Capital | 9 美元 → 3 美元 | 维护 | 跑赢大盘 |
| 03/31/2023 | 661.2% | 瑞士信贷 | 8 美元 → 7 美元 | 维护 | 跑赢大盘 |
| 2022 年 7 月 12 日 | 769.94% | 瑞士信贷 | 10 美元 → 8 美元 | 维护 | 跑赢大盘 |
| 12/02/2022 | 1096.17% | HC Wainwright & Co. | → 11 美元 | 启动覆盖范围开启 | → 购买 |
| 03/31/2022 | 1204.92% | BMO Capital | 18 美元 → 12 美元 | 维护 | 跑赢大盘 |
| 11/19/2021 | 1857.37% | BMO Capital | → 18 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 08/23/2021 | 878.69% | 瑞银（UBS） | → 9 美元 | 启动覆盖范围开启 | → 购买 |
| 08/23/2021 | 2292.34% | 杰富瑞集团 | → 22 美元 | 启动覆盖范围开启 | → 购买 |
| 08/23/2021 | 1531.14% | 瑞士信贷 | → 15 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
What is the target price for Candel Therapeutics (CADL)?
Candel Therapeutics（CADL）的目标价格是多少？
The latest price target for Candel Therapeutics (NASDAQ: CADL) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $11.00 expecting CADL to rise to within 12 months (a possible 1096.17% upside). 6 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月13日公布了Candel Therapeutics（纳斯达克股票代码：CADL）的最新目标股价。该分析公司将目标股价定为11.00美元，预计CADL将在12个月内升至12个月内（可能上涨1096.17％）。去年有6家分析公司公布了评级。
What is the most recent analyst rating for Candel Therapeutics (CADL)?
Candel Therapeutics（CADL）的最新分析师评级是多少？
The latest analyst rating for Candel Therapeutics (NASDAQ: CADL) was provided by HC Wainwright & Co., and Candel Therapeutics reiterated their buy rating.
HC Wainwright & Co. 提供了Candel Therapeutics（纳斯达克股票代码：CADL）的最新分析师评级，Candel Therapeutics重申了买入评级。
When is the next analyst rating going to be posted or updated for Candel Therapeutics (CADL)?
Candel Therapeutics（CADL）的下一次分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Candel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Candel Therapeutics was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Candel Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Candel Therapeutics的最新评级是在2023年11月13日公布的，因此您应该预计下一个评级将在2024年11月13日左右公布。
Is the Analyst Rating Candel Therapeutics (CADL) correct?
分析师对Candel Therapeutics（CADL）的评级是否正确？
While ratings are subjective and will change, the latest Candel Therapeutics (CADL) rating was a reiterated with a price target of $0.00 to $11.00. The current price Candel Therapeutics (CADL) is trading at is $0.92, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Candel Therapeutics（CADL）评级得到了重申，目标股价为0.00美元至11.00美元。Candel Therapeutics（CADL）目前的交易价格为0.92美元，在分析师的预测区间内。